RU2011101661A - Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний - Google Patents
Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний Download PDFInfo
- Publication number
- RU2011101661A RU2011101661A RU2011101661/04A RU2011101661A RU2011101661A RU 2011101661 A RU2011101661 A RU 2011101661A RU 2011101661/04 A RU2011101661/04 A RU 2011101661/04A RU 2011101661 A RU2011101661 A RU 2011101661A RU 2011101661 A RU2011101661 A RU 2011101661A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- xrpd
- Prior art date
Links
- 102000019034 Chemokines Human genes 0.000 title claims abstract 3
- 108010012236 Chemokines Proteins 0.000 title claims abstract 3
- 201000010099 disease Diseases 0.000 title claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 3
- 230000001404 mediated effect Effects 0.000 title claims abstract 3
- WJJBIYLGJUVNJX-UHFFFAOYSA-N pyrimidine-2-sulfonamide Chemical class NS(=O)(=O)C1=NC=CC=N1 WJJBIYLGJUVNJX-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 23
- 150000003839 salts Chemical class 0.000 claims abstract 19
- 125000006239 protecting group Chemical group 0.000 claims abstract 10
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract 4
- 208000001132 Osteoporosis Diseases 0.000 claims abstract 4
- 201000004681 Psoriasis Diseases 0.000 claims abstract 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract 4
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract 4
- 208000006673 asthma Diseases 0.000 claims abstract 4
- 230000015572 biosynthetic process Effects 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 4
- 201000008482 osteoarthritis Diseases 0.000 claims abstract 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 4
- 239000002904 solvent Substances 0.000 claims abstract 4
- 150000001412 amines Chemical class 0.000 claims abstract 2
- 239000002585 base Substances 0.000 claims abstract 2
- 239000003054 catalyst Substances 0.000 claims abstract 2
- 239000003085 diluting agent Substances 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 229940124530 sulfonamide Drugs 0.000 claims abstract 2
- 150000003456 sulfonamides Chemical class 0.000 claims abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 12
- 238000012986 modification Methods 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 238000002648 combination therapy Methods 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- QVKPEMXUBULFBM-YNODCEANSA-N C[C@H](C(CO)O)Nc1cc(NS(N2CCC2)(=O)=O)nc(SCc(cccc2F)c2F)n1 Chemical compound C[C@H](C(CO)O)Nc1cc(NS(N2CCC2)(=O)=O)nc(SCc(cccc2F)c2F)n1 QVKPEMXUBULFBM-YNODCEANSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8121308P | 2008-07-16 | 2008-07-16 | |
| US61/081,213 | 2008-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011101661A true RU2011101661A (ru) | 2012-08-27 |
Family
ID=41011976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011101661/04A RU2011101661A (ru) | 2008-07-16 | 2009-07-15 | Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100016275A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2315754A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011528030A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110031462A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102159555A (cg-RX-API-DMAC7.html) |
| AR (1) | AR072818A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009272425B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0915908A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2730477A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011000402A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2011101661A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201006824A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010007427A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006024823A1 (en) | 2004-08-28 | 2006-03-09 | Astrazeneca Ab | Pyrimidine sulphonamide derivatives as chemokine receptor modulators |
| CN103097377A (zh) | 2010-07-13 | 2013-05-08 | 阿斯利康(瑞典)有限公司 | N-[2-[[(2,3-二氟苯基)甲基]硫基]-6-{[(1r,2s)-2,3-二羟基-1-甲基丙基]氧基}-4-嘧啶基]-1-氮杂环丁烷磺酰胺的新晶形 |
| EP2731945A1 (en) * | 2011-07-12 | 2014-05-21 | AstraZeneca AB | N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator |
| CN104093713B (zh) * | 2012-02-07 | 2016-11-02 | 霍夫曼-拉罗奇有限公司 | 新氮杂环丁烷衍生物 |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| CA3017345A1 (en) | 2016-03-11 | 2017-09-14 | Ardea Biosciences, Inc. | Cxcr-2 inhibitors for treating crystal arthropathy disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2540356A (en) * | 1949-03-12 | 1951-02-06 | Sharp & Dohme Inc | Sulfonamide derivatives |
| GB866843A (en) * | 1958-12-08 | 1961-05-03 | Ici Ltd | Sulphonamidopyrimidines |
| NL279406A (cg-RX-API-DMAC7.html) * | 1961-06-16 | |||
| NL127990C (cg-RX-API-DMAC7.html) * | 1962-12-29 | |||
| US3457278A (en) * | 1964-10-15 | 1969-07-22 | Geigy Chem Corp | Cyclopropyl-4-sulfanilamido-pyrimidines |
| US3452018A (en) * | 1966-08-29 | 1969-06-24 | American Home Prod | 1 - (2 - substituted - 6 - arylsulfonamidopyrimidin - 4 - yl)pyridinium hydroxide inner salts |
| US3673184A (en) * | 1970-09-02 | 1972-06-27 | Dainippon Pharmaceutical Co | Certain 2-substituted-5,8-dihydro-5-oxopyrido{8 2,3-d{9 pyrimidine-6-carboxylic acid derivatives |
| GB2359551A (en) * | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0217431D0 (en) * | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| ES2295685T3 (es) * | 2002-08-24 | 2008-04-16 | Astrazeneca Ab | Derivados de pirimidina como moduladores de la actividad del receptor de quimioquinas. |
| GB0401269D0 (en) * | 2004-01-21 | 2004-02-25 | Astrazeneca Ab | Compounds |
| GB0419235D0 (en) * | 2004-08-28 | 2004-09-29 | Astrazeneca Ab | Compounds |
| WO2006024823A1 (en) * | 2004-08-28 | 2006-03-09 | Astrazeneca Ab | Pyrimidine sulphonamide derivatives as chemokine receptor modulators |
| JP2006137723A (ja) * | 2004-11-15 | 2006-06-01 | Kyowa Hakko Kogyo Co Ltd | スルホンアミド誘導体 |
-
2009
- 2009-07-15 US US12/503,433 patent/US20100016275A1/en not_active Abandoned
- 2009-07-15 CN CN2009801361926A patent/CN102159555A/zh active Pending
- 2009-07-15 BR BRPI0915908A patent/BRPI0915908A2/pt not_active IP Right Cessation
- 2009-07-15 MX MX2011000402A patent/MX2011000402A/es not_active Application Discontinuation
- 2009-07-15 TW TW098123883A patent/TW201006824A/zh unknown
- 2009-07-15 KR KR1020117000994A patent/KR20110031462A/ko not_active Withdrawn
- 2009-07-15 AU AU2009272425A patent/AU2009272425B2/en not_active Ceased
- 2009-07-15 JP JP2011518009A patent/JP2011528030A/ja active Pending
- 2009-07-15 EP EP09785332A patent/EP2315754A1/en not_active Withdrawn
- 2009-07-15 CA CA2730477A patent/CA2730477A1/en not_active Abandoned
- 2009-07-15 WO PCT/GB2009/050856 patent/WO2010007427A1/en not_active Ceased
- 2009-07-15 RU RU2011101661/04A patent/RU2011101661A/ru not_active Application Discontinuation
- 2009-07-16 AR ARP090102722A patent/AR072818A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2730477A1 (en) | 2010-01-21 |
| TW201006824A (en) | 2010-02-16 |
| AR072818A1 (es) | 2010-09-22 |
| EP2315754A1 (en) | 2011-05-04 |
| AU2009272425B2 (en) | 2012-02-02 |
| WO2010007427A1 (en) | 2010-01-21 |
| BRPI0915908A2 (pt) | 2018-07-10 |
| AU2009272425A1 (en) | 2010-01-21 |
| US20100016275A1 (en) | 2010-01-21 |
| MX2011000402A (es) | 2011-03-15 |
| KR20110031462A (ko) | 2011-03-28 |
| CN102159555A (zh) | 2011-08-17 |
| JP2011528030A (ja) | 2011-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI844568B (zh) | 抑制shp2活性化合物之製造方法、及由酸加成產生之產物 | |
| CN100369894C (zh) | 氧化氮合酶抑制剂磷酸盐 | |
| RU2011101661A (ru) | Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний | |
| JP2022119990A (ja) | アポトーシス誘発剤 | |
| JP2019529490A5 (cg-RX-API-DMAC7.html) | ||
| CN111836805A (zh) | 吡啶衍生物及其用于治疗hiv感染的用途 | |
| JP2018515495A5 (cg-RX-API-DMAC7.html) | ||
| RU2005123802A (ru) | Производные адамантана, способы их получения и содержащие их фармацевтические композиции | |
| JP2013010792A5 (cg-RX-API-DMAC7.html) | ||
| JP2015522589A5 (cg-RX-API-DMAC7.html) | ||
| JP2020506951A5 (cg-RX-API-DMAC7.html) | ||
| RU2009104764A (ru) | Производные пурина, как антангонисты a2a | |
| JP2005505618A5 (cg-RX-API-DMAC7.html) | ||
| JP2014500861A5 (cg-RX-API-DMAC7.html) | ||
| CN1227233C (zh) | 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法 | |
| RU2011136250A (ru) | Низкомолекулярное полисульфатированное производное гиалуроновой кислоты и содержащее его лекарственное средство | |
| JP2017524733A5 (cg-RX-API-DMAC7.html) | ||
| JP2010530403A5 (cg-RX-API-DMAC7.html) | ||
| RU2005101406A (ru) | Производные пиримидинсульфонамида в качестве модуляторов рецепторов хемокинов | |
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
| JP2014530818A5 (cg-RX-API-DMAC7.html) | ||
| TWI706949B (zh) | (３-胺基-環氧丙-３-基甲基)-[２-(５,５-二氧-５,６,７,９-四氫-５入*６*-硫-８-氮雜-苯并環庚烯-８-基)-６-甲基-喹唑啉-４-基]-胺之新穎晶形 | |
| JP2015509075A5 (cg-RX-API-DMAC7.html) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2021501756A5 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20131106 |